Identifying High-Risk Tumors within AJCC Stage IB–III Melanomas Using a Seven-Marker Immunohistochemical Signature

by Robin Reschke, Philipp Gussek, Mirjana Ziemer
Published 2021-06-01

Facial Pyoderma Gangrenosum in Senescence

by Dorothea Kratzsch, Mirjana Ziemer, Linda Milkova, Justinus A. Wagner, Jan C. Simon, Michael Kendler
Published 2013-10-01

Posttranslational Modifications of Transthyretin Are Serum Markers in Patients with Mycosis Fungoides

by Niko Escher, Martin Kaatz, Christian Melle, Christina Hipler, Mirjana Ziemer, Dominik Driescht, Uwe Wollina, Ferdinand von Eggeling
Published 2007-03-01

Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy

by Robin Reschke, Philipp Gussek, Andreas Boldt, Ulrich Sack, Ulrike Köhl, Florian Lordick, Thomas Gora, Markus Kreuz, Kristin Reiche, Jan-Christoph Simon, Mirjana Ziemer, Manfred Kunz
Published 2021-07-01

Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study

by Carola Berking, Thomas K Eigentler, Andrea Forschner, Georg Richtig, Erika Richtig, Stefan Diem, Benjamin Weide, Bernhard Klumpp, Claus Garbe, Lukas Flatz, Patrick Terheyden, Lydia Reinhardt, Friedegund Meier, Carmen Loquai, Ulrike Leiter, Van Anh Nguyen, Martin Röcken, Mirjana Ziemer, Nikolaus B Wagner, Max M Lenders, Kathrin Kühl, Fiona André, Milena Dudda, Natalie Ring, Chiara Ebel, Ramon Stäger, Caroline Zellweger, Roland Lang, Michael Paar, Philipp Gussek, Suzan H Stürmer, Susanne Kimeswenger, Angela Oellinger, Maximilian Gassenmaier, Amadeus Schraag, Wolfram Hoetzenecker, Johanna Mangana, Christoffer Gebhardt, Antonio Cozzio
Published 2021-05-01